The effects of CaCO
3 on renal osteodystrophy (ROD) were investigated in non-diabetic patients with chronic renal failure in the predialytic stage (Ccr<30 ml/min, non-HD group, N=7) and undergoing maintenance hemodialysis (HD group, N=6) not treated with phosphate binder and vitamin D metabolites. In the non-HD group, the levels of serum total calcium and ionized calcium (Ca
++) were significantly increased and the levels of serum phosphate (Pi), calcium×phosphate product (Ca×Pi), C-terminal parathyroid hormone (C-PTH) and N-terminal parathyroid hormone (N-PTH) were meaningfully decreased on the 4th week after CaCO
3 3.0 g/day administration. One of the non-HD group, however, had a deterioration of renal function. In the HD group, there was no significant change on the 4th week. CaCO
3 was effective as phosphate binder except some of the HD group. Although we think that the therapy of ROD is necessary at the time of Ccr 30 ml/min in respect of calcium metabolism, aggravation of renal function due to hypercalcemia or elevation of Ca×Pi needs a care. It is, therefore, desirable that CaCO
3 is used from a little. In the patients of the non-HD group with the decrease of serum 1-25 dihydroxycholecalciferol concentration (1-25 (OH)
2D
3), it is suggested that (1-25 (OH)
2D
3) increase reciprocally because of the decrease of Pi for CaCO
3 administration, so that Ca rise owing to the increment of intestinal absorption of calcium and bone resorption, finally C-PTH and N-PTH diminish.
View full abstract